



Galectin 1 Market & Interleukin 15 Industry Therapeutics Development Analysis Research Report

Latest market research report on “Galectin 1 Pipeline Review, H2 2016” and “Interleukin 15 (IL15) Pipeline Review, H2 2016” available with OrbisResearch.com.

DALLAS, TEXAS, UNITED STATES, January 25, 2017 /EINPresswire.com/ -- Galectin 1 (14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside Binding Lectin L 14 I or Galaptin or HBL or HPL or Lactose Binding Lectin 1 or Lectin Galactoside Binding Soluble 1 or Putative MAPK Activating Protein PM12 or S Lac Lectin 1 or LGALS1) - Pipeline Review, H2 2016

Global Markets Direct's, 'Galectin 1 (14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside Binding Lectin L 14 I or Galaptin or HBL or HPL or Lactose Binding Lectin 1 or Lectin Galactoside Binding Soluble 1 or Putative MAPK Activating Protein PM12 or S Lac Lectin 1 or LGALS1) - Pipeline Review, H2 2016', provides in depth analysis on Galectin 1 (14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside Binding Lectin L 14 I or Galaptin or HBL or HPL or Lactose Binding Lectin 1 or Lectin Galactoside Binding Soluble 1 or Putative MAPK Activating Protein PM12 or S Lac Lectin 1 or LGALS1) targeted pipeline therapeutics.

Browse the complete report at <http://www.orbisresearch.com/reports/index/galectin-1-14-kda-laminin-binding-protein-or-14-kda-lectin-or-beta-galactoside-binding-lectin-l-14-i-or-galaptin-or-hbl-or-hpl-or-lactose-binding-lectin-1-or-lectin-galactoside-binding-soluble-1-or-putative-mapk-activating-protein-pm12-or-s-lac-lectin-1-o> .

The report provides comprehensive information on the Galectin 1 (14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside Binding Lectin L 14 I or Galaptin or HBL or HPL or Lactose Binding Lectin 1 or Lectin Galactoside Binding Soluble 1 or Putative MAPK Activating Protein PM12 or S Lac Lectin 1 or LGALS1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Galectin 1 (14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside Binding Lectin L 14 I or Galaptin or HBL or HPL or Lactose Binding Lectin 1 or Lectin Galactoside Binding Soluble 1 or Putative MAPK Activating Protein PM12 or S Lac Lectin 1 or LGALS1) targeted therapeutics development and features dormant and discontinued projects.

Request a sample of this report at <http://www.orbisresearch.com/contacts/request-sample/184595> .

Companies Mentioned in the report are Galectin Therapeutics Inc, GlycoMimetics Inc, and PepTx Inc .

Another report on 'Interleukin 15 (IL15) - Pipeline Review, H2 2016', provides in depth analysis on Interleukin 15 (IL15) targeted pipeline therapeutics.

The report provides comprehensive information on the Interleukin 15 (IL15) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 15 (IL15) targeted therapeutics development and features dormant and discontinued projects.

Browse the complete report at <http://www.orbisresearch.com/reports/index/interleukin-15-il15-pipeline-review-h2-2016> .

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Request a sample of this report at <http://www.orbisresearch.com/contacts/request-sample/184598> .

Companies Mentioned in the report are Amgen Inc, ARMO Biosciences Inc, Calypso Biotech SA, Novartis, AG, ZIOPHARM Oncology Inc .

About Us:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Hector Costello
Orbis Research
+1 (214) 884-6817
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2018 IPD Group, Inc. All Right Reserved.